AbbVie Inc.
For the period ended Dec 31, 2025. Filed Feb 20, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 20, 2026
ABBV$293.89+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Earnings
| years ended December 31 (in millions, except per share data) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net revenues | $61,160 | $56,334 | $54,318 |
| Cost of products sold | 18,204 | 16,904 | 20,415 |
| Selling, general and administrative | 14,010 | 14,752 | 12,872 |
| Research and development | 9,096 | 12,791 | 7,675 |
| Acquired IPR&D and milestones | 5,016 | 2,757 | 778 |
| Other operating income | (241) | (7) | (179) |
| Total operating costs and expenses | 46,085 | 47,197 | 41,561 |
| Operating earnings | 15,075 | 9,137 | 12,757 |
| Interest expense, net | 2,627 | 2,160 | 1,684 |
| Net foreign exchange loss | 58 | 21 | 146 |
| Other expense, net | 5,793 | 3,240 | 4,677 |
| Earnings before income tax expense | 6,597 | 3,716 | 6,250 |
| Income tax expense (benefit) | 2,364 | (570) | 1,377 |
| Net earnings | 4,233 | 4,286 | 4,873 |
| Net earnings attributable to noncontrolling interest | 7 | 8 | 10 |
| Net earnings attributable to AbbVie Inc. | $4,226 | $4,278 | $4,863 |
| Per share data | |||
| Basic earnings per share attributable to AbbVie Inc. | $2.37 | $2.40 | $2.73 |
| Diluted earnings per share attributable to AbbVie Inc. | $2.36 | $2.39 | $2.72 |
| Weighted-average basic shares outstanding | 1,769 | 1,769 | 1,768 |
| Weighted-average diluted shares outstanding | 1,773 | 1,773 | 1,773 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.